Site Editor

Rebecca Olin, MD, MS


Keith W. Pratz, MD, on Reaching Composite Complete Response With Venetoclax/Azacitidine: What It Means for Patients With AML

Posted: Wednesday, July 7, 2021

Keith W. Pratz, MD, of the University of Pennsylvania, discusses the clinical implications of his study findings on patients with acute myeloid leukemia who were treated with venetoclax and azacitidine and achieved both composite complete remission and measurable residual disease of < 10-3. The outcomes of these patients might be used to guide therapeutic decisions and/or provide more accurate prognoses.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.